SCHEMBL30920753

SCHEMBL30920753

Cc1ccc(S(=O)(=O)n2c(CNC(=O)OC(C)(C)C)cc3cc(OC(F)(F)F)c(C=O)cc32)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 7/20 0.38
▸ PPARA Q07869 6/20 0.38
▸ PPARD Q03181 5/20 0.38
▸ CYP2D6 P10635 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ MTNR1B P49286 1/20 0.33
▸ RORC P51449 2/20 0.33
▸ BRD4 O60885 1/20 0.33
▸ NOD2 Q9HC29 1/20 0.33
▸ NOD1 Q9Y239 1/20 0.33
▸ CA12 O43570 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ CA9 Q16790 1/20 0.33
▸ ACLY P53396 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27247415 0.89 PPARG (0.40) PPARGPPARAPPARDCYP2D6KDM4E
SCHEMBL30920190 0.88 PPARG (0.39) PPARGPPARAPPARDCYP2D6KDM4E
SCHEMBL30920806 0.87 MTNR1B (0.40) PPARGPPARAPPARDCYP2D6KDM4E
SCHEMBL30920853 0.86 PPARG (0.42) PPARGPPARAPPARDCYP2D6KDM4E
SCHEMBL30920287 0.85 PPARG (0.33) PPARGPPARAPPARDCYP2D6MTNR1B
SCHEMBL30920138 0.81 PPARG (0.34) PPARGPPARAPPARDCYP2D6MTNR1B
SCHEMBL30920919 0.80 CYP2D6 (0.41) PPARGPPARAPPARDCYP2D6KDM4E
SCHEMBL30920644 0.80 MTNR1B (0.41) PPARGPPARAPPARDCYP2D6MTNR1B
SCHEMBL27247860 0.80 PPARG (0.39) PPARGPPARAPPARDKDM4ELMNA
SCHEMBL30920714 0.79 PPARG (0.39) PPARGPPARAPPARDKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4601635-A2 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF Maze Therapeutics, Inc. (US) 2025-08-20 — — EP disclosed
US-20240199546-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF HERCULES CAPITAL, INC., AS AGENT 2024-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199546-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF SLC6A19, SLC2A9, SLC6A3 PPARG 4723/4885PPARA 4686/4885PPARD 4749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback